SCHEMBL1897659

SCHEMBL1897659

c1ccc2c(c1)CC1CNCC21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 5/20 0.59
CHRNB2 P17787 2/20 0.49
CHRNA4 P43681 2/20 0.49
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41
GRIN2B Q13224 1/20 0.41
GRIN2C Q14957 1/20 0.41
GRIN3A Q8TCU5 1/20 0.41
HTR2A P28223 4/20 0.39
HTR2B P41595 4/20 0.39
HRH3 Q9Y5N1 2/20 0.38
MEN1 O00255 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
KMT2A Q03164 1/20 0.38
SIGMAR1 Q99720 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9278829 1.00 HTR2C (0.59) HTR2CCHRNB2CHRNA4CHRNB4CHRNA3
Hydrochloric Acid SCHEMBL9672275 0.98 HTR2C (0.57) HTR2CCHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL7376647 0.83 HTR2C (0.42) HTR2CCHRNB2CHRNA4HTR2AHTR2B
SCHEMBL1047199 0.83 HTR2C (0.42) HTR2CCHRNB2CHRNA4HTR2AHTR2B
SCHEMBL29613747 0.83 HTR2C (0.42) HTR2CCHRNB2CHRNA4HTR2AHTR2B
SCHEMBL852627 0.82 MEN1 (0.53) HTR2CCHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL1724839 0.81 SIGMAR1 (0.49) HTR2CHTR2AHTR2BSIGMAR1
SCHEMBL1893906 0.80 HTR2C (0.42) HTR2CCHRNB2CHRNA4CHRNB4CHRNA3
Hydrochloric Acid SCHEMBL1722276 0.79 SIGMAR1 (0.50) HTR2CHTR2AHTR2BSIGMAR1
SCHEMBL3886033 0.78 BPTF (0.45) HTR2CCHRNB2CHRNA4CHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096520-B2 Tricyclic ideno-pyrrole derivatives as serotonin receptor modulators ABT HOLDING COMPANY (US) 2015-08-04 US claimed
US-20140206739-A1 TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS ABT HOLDING COMPANY (US) 2014-07-24 US claimed
US-20110172283-A1 Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators BENNANI YOUSSEF L 2011-07-14 US claimed
US-20090239925-A1 TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS ATHERSYS, INC. 2009-09-24 US claimed
US-20060025601-A1 Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators ATHERSYS, INC. 2006-02-02 US claimed
EP-0422134-B1 5-HT SELECTIVE AGENTS ABBOTT LAB (US) 1996-06-12 EP claimed
EP-0422134-A4 5-HT SELECTIVE AGENTS 1992-05-06 EP claimed
EP-0422134-A1 5-HT SELECTIVE AGENTS. ABBOTT LAB (US) 1991-04-17 EP claimed
WO-1990006927-A1 5-HT SELECTIVE AGENTS ABBOTT LABORATORIES (US) 1990-06-28 WO claimed
JP-61037767-A None JP disclosed
US-9096520-B2 Tricyclic ideno-pyrrole derivatives as serotonin receptor modulators ABT HOLDING COMPANY (US) 2015-08-04 US disclosed
US-9096520-B2 Tricyclic ideno-pyrrole derivatives as serotonin receptor modulators ABT HOLDING COMPANY (US) 2015-08-04 US disclosed
US-9096520-B2 Tricyclic ideno-pyrrole derivatives as serotonin receptor modulators ABT HOLDING COMPANY (US) 2015-08-04 US disclosed
US-20140206739-A1 TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS ABT HOLDING COMPANY (US) 2014-07-24 US disclosed
EP-0170093-A1 1,2,3,3a,8,8a-Hexahydro-Indeno-(1,2-c)Pyrrdes ABBOTT LABORATORIES (US) 1986-02-05 EP disclosed
EP-0170093-A1 1,2,3,3a,8,8a-Hexahydro-Indeno-(1,2-c)Pyrrdes ABBOTT LABORATORIES (US) 1986-02-05 EP disclosed
US-4511575-A Antidiabetic pyrrolecarboxylic acids PFIZER INC. (US) 1985-04-16 US disclosed
US-4511576-A Antidiabetic pyrrolecarboxylic acids PFIZER INC. (US) 1985-04-16 US disclosed
US-4282242-A HYPOGLYCEMIC AGENTS PFIZER INC. (US) 1981-08-04 US disclosed
US-4282246-A Antidiabetic furancarboxylic and thiphenecarboxylic acids PFIZER INC. (US) 1981-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172283-A1 Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators HTR5A, HTR3E, HTR1E HTR2C 6/4885CHRNB2 1042/4885CHRNA4 388/4885
US-20060025601-A1 Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators HTR5A, HTR3E, HTR1E HTR2C 6/4885CHRNB2 1042/4885CHRNA4 388/4885
US-20090239925-A1 TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS HTR5A, HTR3E, HTR1E HTR2C 6/4885CHRNB2 1042/4885CHRNA4 388/4885
US-20140206739-A1 TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS HTR5A, HTR3E, HTR1E HTR2C 6/4885CHRNB2 1042/4885CHRNA4 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.